€27.10
1.50% day before yesterday
Xetra, Sep 06, 05:36 pm CET
ISIN
DE0005227235
Symbol
BIO3
Index
Sector

BIOTEST AG Stock price

€27.10
+0.80 3.04% 1M
-0.70 2.52% 6M
-3.90 12.58% YTD
-4.10 13.14% 1Y
-7.40 21.45% 3Y
+4.80 21.52% 5Y
-59.60 68.74% 10Y
Xetra, Closing price Fri, Sep 06 2024
+0.40 1.50%
ISIN
DE0005227235
Symbol
BIO3
Index
Sector

Key metrics

Market capitalization €1.07b
Enterprise Value €1.63b
P/E (TTM) P/E ratio 6.52
EV/Sales (TTM) EV/Sales 2.09
P/S ratio (TTM) P/S ratio 1.37
P/B ratio (TTM) P/B ratio 2.00
Dividend yield 0.15%
Last dividend (FY24) €0.04
Revenue growth (TTM) Revenue growth 45.17%
Revenue (TTM) Revenue €781.30m
EBIT (operating result TTM) EBIT €200.60m
Cash position €66.30m
EPS (TTM) EPS €4.15
Show more

Is BIOTEST AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

BIOTEST AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BIOTEST AG:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast BIOTEST AG:

Hold
100%

Financial data from BIOTEST AG

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
781 781
55% 55%
100%
- Direct Costs 432 432
2% 2%
55%
349 349
339% 339%
45%
- Selling and Administrative Expenses 84 84
1% 1%
11%
- Research and Development Expense 65 65
27% 27%
8%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 201 201
466% 466%
26%
Net Profit 164 164
337% 337%
21%

In millions EUR.

Don't miss a Thing! We will send you all news about BIOTEST AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BIOTEST AG Stock News

EQS
3 days ago
Biotest ist ein Anbieter von biologischen Arzneimitteln, die aus menschlichem Plasma gewonnen werden. Mit einer Wertschöpfungskette, die von der vorklinischen und klinischen Entwicklung bis zur weltweiten Vermarktung reicht, hat sich Biotest vorrangig auf die Anwendungsgebiete Klinische Immunolog...
AD HOC NEWS
3 days ago
Biotest AG / DE0005227235
AD HOC NEWS
3 days ago
Biotest AG / DE0005227235
More BIOTEST AG News

Company Profile

Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.

Head office Germany
CEO Peter Janssen
Employees 2,426
Founded 1946
Website www.biotest.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today